Epigral Q4 Results FY26 Record Revenue Rs 736 Crore EBITDA Margin 23 Percent

Epigral Q4 results for FY26 marked a record quarter for India’s leading chlorine derivatives and specialty chemicals manufacturer. Revenue hit Rs 736 crore, up 17% year on year, the highest quarterly revenue in the company’s history. The Epigral Q4 results were supported by strong demand for CPVC resin, chloromethanes, and downstream derivatives from domestic and export markets.

The Epigral Q4 results FY26 also demonstrated robust profitability with PAT at Rs 82 crore and an EBITDA margin of 23%, reflecting healthy realisations and operational efficiency in its integrated chlor-alkali complex. The Epigral Q4 results board declared a dividend of Rs 5 per share for FY26, a signal of strong cash flows.

Get Free Stock Recommendations on Univest

Epigral Q4 FY26 Results at a Glance

Metric	Q4 FY26	Change / Context
Revenue	Rs 736 crore	+17% YoY, record quarter
Net Profit PAT	Rs 82 crore	Strong profitability
EBITDA Margin	23%	Healthy realisations
Dividend	Rs 5 per share	FY26 payout
CPVC Resin Sales	Growing volumes	Key product
Export Contribution	Meaningful	Diversified revenue

Track live Epigral financials, analyst ratings and peer comparisons on the Univest Screener.

Key Highlights from Epigral Q4 FY26 Results

Record Revenue Milestone for Epigral

The Epigral Q4 results FY26 reported revenue of Rs 736 crore, up 17% year on year, the highest quarterly revenue in the company’s history. The Epigral Q4 results milestone was driven by strong domestic demand from the construction and water treatment sectors alongside growing export shipments of chloromethanes and CPVC resin, confirming the company’s scaling trajectory.

EBITDA Margin at 23 Percent in Q4 FY26

EBITDA margin in the Epigral Q4 results FY26 came in at 23%, reflecting healthy caustic soda and CPVC resin realisations. The integrated chlor-alkali model provides Epigral with a natural cost hedge. The Epigral Q4 results show that margin management has improved significantly and the company is sustaining profitability through the full product cycle.

What Drove Epigral Q4 FY26 Performance

Epigral Q4 results were driven by healthy pricing for CPVC resin, sustained chloromethane demand from pharmaceutical and refrigerant sectors, and caustic soda demand from alumina and textile industries. The company’s expanding downstream product portfolio reduces reliance on any single commodity cycle, a key theme in the Epigral Q4 results over recent years. This diversification supports earnings stability.

Dividend and Shareholder Returns

Epigral declared a dividend of Rs 5 per share for FY26 as part of the Epigral Q4 results announcement. The company’s strong free cash flow generation from its integrated chemical operations enables a consistent dividend policy while also funding capacity expansion projects that will support future revenue growth beyond the Epigral Q4 results FY26 base.

Outlook for FY27

Following the Epigral Q4 results FY26, the company is well-positioned for continued growth in FY27. New capacity in ECU and downstream derivatives is expected to come onstream progressively. The Epigral Q4 results management commentary indicates that EBITDA margins are expected to sustain in the 22 to 24% range as realisation environment remains supportive.

Conclusion

Epigral Q4 results FY26 delivered a record-breaking quarter with revenue at Rs 736 crore up 17%, PAT at Rs 82 crore, EBITDA margin at 23%, and a dividend of Rs 5 per share. The Epigral Q4 results FY26 confirm the company’s strength as India’s leading integrated chlor-alkali and specialty chemicals manufacturer. FY27 new capacity additions and stable downstream realisations make the Epigral Q4 results a strong foundation for continued growth.

Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.

Frequently Asked Questions

What was Epigral Q4 FY26 revenue?

Epigral Q4 results FY26 showed record revenue of Rs 736 crore, up 17% year on year, driven by CPVC resin, chloromethanes, and caustic soda demand from domestic and export markets.

What is Epigral EBITDA margin in Q4 FY26?

EBITDA margin in Epigral Q4 results FY26 was 23%, reflecting healthy product realisations and the cost efficiency of its integrated chlor-alkali manufacturing complex in Gujarat.

What dividend did Epigral declare for FY26?

Epigral declared a dividend of Rs 5 per share for FY26, reflecting strong cash flow generation from its chemicals business as highlighted in the Epigral Q4 results FY26.

What products drive Epigral revenue?

Epigral Q4 results FY26 revenue was driven by CPVC resin, chloromethanes, caustic soda, and other chlorine derivatives used in construction, pharma, and industrial sectors.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026